Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE2 | Q9BYF1 | 3/20 | 0.43 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
| ▸ | PREP | P48147 | 3/20 | 0.38 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.38 |
| ▸ | CTSL | P07711 | 1/20 | 0.37 |
| ▸ | CTSB | P07858 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.37 |
| ▸ | CTSK | P43235 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4968962 | 0.87 | SIGMAR1 (0.52) | ACE2SIGMAR1CHRM2CHRM5CHRM1 | |
| SCHEMBL4968449 | 0.84 | SIGMAR1 (0.41) | ACE2SIGMAR1CHRM2CHRM5CHRM1 | |
| SCHEMBL4967291 | 0.83 | TMEM97 (0.44) | ACE2SIGMAR1TRPM8CHRM5TMEM97 | |
| SCHEMBL4964958 | 0.82 | TMEM97 (0.47) | SIGMAR1TRPM8CHRM2CHRM5CHRM1 | |
| SCHEMBL4964959 | 0.78 | HSD17B10 (0.39) | SIGMAR1PREPCHRM2CHRM5CHRM1 | |
| SCHEMBL4964479 | 0.75 | GLA (0.45) | SIGMAR1TRPM8CTSLCTSBCTSS | |
| SCHEMBL4078596 | 0.74 | CASP3 (0.52) | PREPCTSLCTSBCTSK | |
| SCHEMBL4077350 | 0.74 | CASP3 (0.52) | PREPCTSLCTSBCTSK | |
| SCHEMBL4077352 | 0.74 | CASP3 (0.52) | PREPCTSLCTSBCTSK | |
| SCHEMBL4082421 | 0.71 | CASP3 (0.56) | PREPCTSLCTSBCTSK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1489088-B1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | NIPPON KAYAKU KK (JP) | 2008-08-13 | — | — | EP | disclosed |
| US-7348318-B2 | α-Amino-N-(diaminophosphinyl)lactam derivatives | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2008-03-25 | — | — | US | disclosed |
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | NIPPON KAYAKU KABUSHIKI KAISHA (JP) | 2005-07-28 | — | — | US | disclosed |
| EP-1489088-A1 | NOVEL ALPHA-AMINO-N-(DIAMINOPHOSPHINYL)LACTAM DERIVATIVE | Nippon Kayaku Kabushiki Kaisha (JP) | 2004-12-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050164989-A1 | Novel $g(a)-amino-n-(diaminophosphinyl) lactam derivative | DNPEP, PEPD, ANPEP | ACE2 332/4885SIGMAR1 2845/4885PREP 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.